BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 236 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q2 2023. The put-call ratio across all filers is 0.21 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $429,282 | +0.6% | 60,633 | 0.0% | 0.03% | +3.8% |
| Q2 2023 | $426,857 | -15.6% | 60,633 | 0.0% | 0.03% | -18.8% |
| Q1 2023 | $505,680 | -27.4% | 60,633 | 0.0% | 0.03% | -31.9% |
| Q4 2022 | $696,067 | -8.9% | 60,633 | 0.0% | 0.05% | -16.1% |
| Q3 2022 | $764,000 | +19.2% | 60,633 | 0.0% | 0.06% | +24.4% |
| Q2 2022 | $641,000 | -35.0% | 60,633 | 0.0% | 0.04% | -21.1% |
| Q1 2022 | $986,000 | +17.4% | 60,633 | 0.0% | 0.06% | +11.8% |
| Q4 2021 | $840,000 | +94.9% | 60,633 | +102.1% | 0.05% | +75.9% |
| Q3 2021 | $431,000 | +36.4% | 30,000 | +50.0% | 0.03% | +38.1% |
| Q2 2021 | $316,000 | +55.7% | 20,000 | 0.0% | 0.02% | +31.2% |
| Q1 2021 | $203,000 | -17.8% | 20,000 | -39.7% | 0.02% | -20.0% |
| Q4 2020 | $247,000 | +116.7% | 33,157 | 0.0% | 0.02% | +100.0% |
| Q3 2020 | $114,000 | +20.0% | 33,157 | +65.8% | 0.01% | +11.1% |
| Q2 2020 | $95,000 | +137.5% | 20,000 | 0.0% | 0.01% | +80.0% |
| Q1 2020 | $40,000 | -42.0% | 20,000 | 0.0% | 0.01% | -16.7% |
| Q4 2019 | $69,000 | +21.1% | 20,000 | 0.0% | 0.01% | 0.0% |
| Q3 2019 | $57,000 | -25.0% | 20,000 | 0.0% | 0.01% | -25.0% |
| Q2 2019 | $76,000 | -53.4% | 20,000 | 0.0% | 0.01% | -55.6% |
| Q1 2019 | $163,000 | +1.2% | 20,000 | 0.0% | 0.02% | -18.2% |
| Q4 2018 | $161,000 | +5.9% | 20,000 | 0.0% | 0.02% | -47.6% |
| Q3 2018 | $152,000 | +33.3% | 20,000 | 0.0% | 0.04% | +20.0% |
| Q2 2018 | $114,000 | +20.0% | 20,000 | 0.0% | 0.04% | +9.4% |
| Q1 2018 | $95,000 | -3.1% | 20,000 | 0.0% | 0.03% | -3.0% |
| Q4 2017 | $98,000 | -6.7% | 20,000 | 0.0% | 0.03% | -13.2% |
| Q3 2017 | $105,000 | -5.4% | 20,000 | 0.0% | 0.04% | -13.6% |
| Q2 2017 | $111,000 | -33.9% | 20,000 | 0.0% | 0.04% | -37.1% |
| Q1 2017 | $168,000 | +32.3% | 20,000 | 0.0% | 0.07% | +22.8% |
| Q4 2016 | $127,000 | +44.3% | 20,000 | 0.0% | 0.06% | +54.1% |
| Q3 2016 | $88,000 | +54.4% | 20,000 | 0.0% | 0.04% | +48.0% |
| Q2 2016 | $57,000 | 0.0% | 20,000 | 0.0% | 0.02% | -16.7% |
| Q1 2016 | $57,000 | -72.3% | 20,000 | 0.0% | 0.03% | -72.0% |
| Q4 2015 | $206,000 | -9.6% | 20,000 | 0.0% | 0.11% | -7.8% |
| Q3 2015 | $228,000 | -23.7% | 20,000 | 0.0% | 0.12% | -13.4% |
| Q2 2015 | $299,000 | +65.2% | 20,000 | 0.0% | 0.13% | +63.4% |
| Q1 2015 | $181,000 | +49.6% | 20,000 | +100.0% | 0.08% | +28.1% |
| Q4 2014 | $121,000 | +23.5% | 10,000 | 0.0% | 0.06% | +18.5% |
| Q3 2014 | $98,000 | – | 10,000 | – | 0.05% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RP Management, LLC | 3,846,154 | $62,538,000 | 25.44% |
| ORACLE INVESTMENT MANAGEMENT INC | 1,720,733 | $27,979,000 | 5.53% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 57,000 | $19,282,000 | 4.35% |
| MPM BioImpact LLC | 639,089 | $10,392,000 | 2.79% |
| Parkman Healthcare Partners LLC | 476,978 | $7,756,000 | 2.27% |
| Sarissa Capital Management LP | 1,390,790 | $22,614,000 | 2.14% |
| Ghost Tree Capital, LLC | 350,000 | $5,691,000 | 1.24% |
| Lisanti Capital Growth, LLC | 662,644 | $10,775,000 | 1.21% |
| Baker Brothers Advisors | 12,710,818 | $206,678,000 | 1.19% |
| Tamarack Advisers, LP | 125,000 | $2,033,000 | 0.96% |